基本情報
- 標準SMILES
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1- InChIKey
NDAUXUAQIAJITI-LBPRGKRZSA-N- 分子式
- C13H21NO3
- 平均分子量
- 239.31 g/mol
- 単同位体質量
- 239.15214353
概要
(R)-salbutamol is an albuterol.
名称と識別子
- 優先名称
- (-)-Salbutamol
- IUPAC
- 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
- 現地名
- レボサルブタモール
- 英語名
- Levalbuterol
- 分子式
- C13H21NO3
- 分子量
- 239.31
名称と別名
名称をさらに表示
データベース識別子
- CAS
34391-04-3- PubChem CID
- 123600
- DTXSID
DTXSID80187964- ChEMBL
CHEMBL1002- ChEBI
CHEBI:8746- UNII
- EDN2NBH5SS
- EC Number
- 608-983-3
- Nikkaji
- J428.072E
物性
構造計算による物性
- XLogP
- 0.3
- 極性表面積
- 72.7 Ų
- 水素結合供与体数
- 4
- 水素結合受容体数
- 4
- 回転可能結合数
- 5
- 重原子数
- 17
- 形式電荷
- 0
- 複雑度
- 227
実験および物理化学的性質
物理化学的性質
- 沸点
- 433.5 · 433.5±40.0 °C(Predicted)
- 比重(密度)
- 1.152 · 1.152±0.06 g/cm3(Predicted)
- 酸解離定数(Pka)
- 9.99 · 9.99±0.31(Predicted)
- InChI
- InChI=1/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/s3
- InChIKey
- NDAUXUAQIAJITI-PLAQIDKDNA-N
- SMILES
- C1(=CC=C(O)C(CO)=C1)[C@@H](O)CNC(C)(C)C |&1:9,r|
- CAS データベース
- 34391 · 34391-04-3(CAS DataBase Reference)
安全と法規制
毒性情報
Toxicity Summary
Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.
安全データ
- risk_code
- 22
- hazard_code
- Xn
- safety_code
- 36
化学と産業
薬理情報
Mechanism of Action
β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.
Metabolism/Metabolites
Pure (R)-salbutamol formulation known as levosalbutamol is metabolised up to 12 times faster than (S)-salbutamol by intestine.
Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate. Route of Elimination: Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite. Half Life: 1.6 hours
FDA Pharmacological Classification
EDN2NBH5SS
LEVALBUTEROL
Mechanisms of Action [MoA] - Adrenergic beta2-Agonists
Established Pharmacologic Class [EPC] - beta2-Adrenergic Agonist
Levalbuterol is a beta2-Adrenergic Agonist. The mechanism of action of levalbuterol is as an Adrenergic beta2-Agonist.
LEVALBUTEROL
Absorption, Distribution and Excretion
Inhalation delivers the medication directly into the airways and lungs, thereby minimizing side effects because of reduced systemic absorption of the inhaled medications.
excreted into the urine.
用途と製造
応用分野
説明Levalbuterol was launched in the US for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. It is the single R-enantiomer version of racemic albuterol (salbutamol) marketed for more than 30 years as a mainstay in the treatment of asthma. The R-isomer can be obtained with an excellent optical purity by enantiomeric purification based on the separation of diastereomeric tartrates. This isomer retains solely the desired bronchodilating effect of the racemic mixture due to a potent agonistic effect on β2-adrenoceptors, with a lower incidence of β- mediated side effects such as pulse rate increase, tremor and decrease in blood glucose and potassium levels. A pivotal clinical trial with two doses of levalbuterol and racemic albuterol, given by nebulization, demonstrated a greater improvement in lung function for the pure enantiomer levalbuterol.
使用(R)-Salbutamol is used in composition and methods to reduce beta-agonist-mediated tachyphylaxis.
上流・下流製品情報
上流原料
サプライヤー36 社
関連反応
関連ノート
読み込み中…